Holst J
J Physiol. 2024; 602(24):6613-6629.
PMID: 39520693
PMC: 11649525.
DOI: 10.1113/JP287461.
Hamed K, Alosaimi M, Ali B, Alghamdi A, Alkhashi T, Alkhaldi S
Cureus. 2024; 16(9):e68390.
PMID: 39355484
PMC: 11444311.
DOI: 10.7759/cureus.68390.
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C
Signal Transduct Target Ther. 2024; 9(1):234.
PMID: 39289339
PMC: 11408715.
DOI: 10.1038/s41392-024-01931-z.
Li Z, Pei L, Xiao H, Chen N, Lai F, Yue S
Endocr Connect. 2024; 13(11).
PMID: 39235859
PMC: 11466252.
DOI: 10.1530/EC-23-0548.
Lee H, Ko S, Park S, Kim K, Kim S, Cho I
Clin Hypertens. 2024; 30(1):24.
PMID: 39217384
PMC: 11366170.
DOI: 10.1186/s40885-024-00279-4.
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
Holst J
Nat Metab. 2024; 6(10):1866-1885.
PMID: 39160334
DOI: 10.1038/s42255-024-01113-9.
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs.
Feng J, Jin T
Med Rev (2021). 2024; 4(4):312-325.
PMID: 39135602
PMC: 11317081.
DOI: 10.1515/mr-2024-0018.
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.
Liu Q
Front Endocrinol (Lausanne). 2024; 15:1431292.
PMID: 39114288
PMC: 11304055.
DOI: 10.3389/fendo.2024.1431292.
Transforming obesity: The advancement of multi-receptor drugs.
Kusminski C, Perez-Tilve D, Muller T, DiMarchi R, Tschop M, Scherer P
Cell. 2024; 187(15):3829-3853.
PMID: 39059360
PMC: 11286204.
DOI: 10.1016/j.cell.2024.06.003.
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism.
Bu T, Sun Z, Pan Y, Deng X, Yuan G
Diabetes Metab J. 2024; 48(3):354-372.
PMID: 38650100
PMC: 11140404.
DOI: 10.4093/dmj.2023.0277.
Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.
Jiang Y, Bai H, Liu G, Wang S, Yin L, Hou Z
Front Endocrinol (Lausanne). 2024; 15:1347684.
PMID: 38524632
PMC: 10958196.
DOI: 10.3389/fendo.2024.1347684.
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.
Novikoff A, Muller T
Physiology (Bethesda). 2024; 39(3):142-156.
PMID: 38353610
PMC: 11368522.
DOI: 10.1152/physiol.00032.2023.
Maternal GLP-1 receptor activation inhibits fetal growth.
Qiao L, Lu C, Zang T, Dzyuba B, Shao J
Am J Physiol Endocrinol Metab. 2024; 326(3):E268-E276.
PMID: 38197791
PMC: 11193516.
DOI: 10.1152/ajpendo.00361.2023.
Appetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity.
Gan H, Cerbone M, Dattani M
Endocr Rev. 2023; 45(3):309-342.
PMID: 38019584
PMC: 11074800.
DOI: 10.1210/endrev/bnad033.
Evolution of GCGR family ligand-receptor extensive cross-interaction systems suggests a therapeutic direction for hyperglycemia in mammals.
Liu J, Wang X, Zhang W, Liao G, Shao Z, Brosius J
Acta Biochim Biophys Sin (Shanghai). 2023; 55(12):1855-1863.
PMID: 37969012
PMC: 10753361.
DOI: 10.3724/abbs.2023133.
Effects of glucagon‑like peptide‑1 receptor agonists on fracture healing in a rat osteoporotic model.
Wang R, Na H, Cheng S, Zheng Y, Yao J, Bian Y
Exp Ther Med. 2023; 26(3):412.
PMID: 37559934
PMC: 10407998.
DOI: 10.3892/etm.2023.12111.
The human α cell in health and disease.
Pettway Y, Saunders D, Brissova M
J Endocrinol. 2023; 258(1).
PMID: 37114672
PMC: 10428003.
DOI: 10.1530/JOE-22-0298.
The expanding incretin universe: from basic biology to clinical translation.
Drucker D, Holst J
Diabetologia. 2023; 66(10):1765-1779.
PMID: 36976349
DOI: 10.1007/s00125-023-05906-7.
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.
Wang J, Wang Q, Yang X, Yang W, Li D, Jin J
Front Endocrinol (Lausanne). 2023; 14:1085799.
PMID: 36843578
PMC: 9945324.
DOI: 10.3389/fendo.2023.1085799.
Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story.
Inceu A, Neag M, Craciun A, Buzoianu A
Int J Mol Sci. 2023; 24(4).
PMID: 36834796
PMC: 9965280.
DOI: 10.3390/ijms24043385.
